精华制药
(002349)
| 流通市值：58.87亿 | | | 总市值：58.87亿 |
| 流通股本：8.14亿 | | | 总股本：8.14亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,045,172,312.93 | 720,309,080.88 | 367,129,069.92 | 1,511,751,346.97 |
| 营业收入 | 1,045,172,312.93 | 720,309,080.88 | 367,129,069.92 | 1,511,751,346.97 |
| 二、营业总成本 | 825,883,624.7 | 542,650,615.21 | 278,288,740.26 | 1,185,197,086.72 |
| 营业成本 | 523,962,973.54 | 354,038,778.24 | 180,783,729.81 | 775,641,663.38 |
| 税金及附加 | 15,466,427.8 | 10,424,469.52 | 5,297,952.98 | 21,304,299.79 |
| 销售费用 | 183,281,978.47 | 116,167,453.94 | 57,956,982.13 | 227,972,947.97 |
| 管理费用 | 86,850,764.65 | 55,928,588.65 | 27,317,858.65 | 118,804,600.3 |
| 研发费用 | 47,149,976.95 | 32,505,972.93 | 17,109,278.74 | 64,619,849.59 |
| 财务费用 | -30,828,496.71 | -26,414,648.07 | -10,177,062.05 | -23,146,274.31 |
| 其中:利息费用 | 2,068,573.35 | 1,458,308.18 | 725,901.36 | 2,573,901.39 |
| 其中:利息收入 | 33,683,811.02 | 26,625,103.95 | 10,041,046.45 | 23,635,092.97 |
| 加:公允价值变动收益 | 3,657,354.18 | 3,409,243.07 | 2,866,682.19 | 6,832,117.8 |
| 加:投资收益 | 1,944,009.37 | 1,596,415.94 | 135,620.88 | 238,448.3 |
| 资产处置收益 | 3,154.45 | 3,154.45 | - | -87,053.73 |
| 资产减值损失(新) | -974,977.34 | -1,255,826.74 | 297,881.36 | -7,949,316.79 |
| 信用减值损失(新) | -2,019,687.02 | -2,565,624.89 | -423,209.94 | -2,028,986.71 |
| 其他收益 | 7,038,178.48 | 6,136,722.05 | 4,180,842.03 | 7,294,715.48 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 228,936,720.35 | 184,982,549.55 | 95,898,146.18 | 330,854,184.6 |
| 加:营业外收入 | 226,024.34 | 173,941.72 | 20,394.78 | 1,086,904.14 |
| 减:营业外支出 | 3,953,336.64 | 2,626,206.34 | 51,111.29 | 2,245,889.68 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 225,209,408.05 | 182,530,284.93 | 95,867,429.67 | 329,695,199.06 |
| 减:所得税费用 | 34,700,369.71 | 27,624,125.05 | 13,884,386.95 | 53,228,550.69 |
| 六、净利润 | 190,509,038.34 | 154,906,159.88 | 81,983,042.72 | 276,466,648.37 |
| 持续经营净利润 | 190,509,038.34 | 154,906,159.88 | 81,983,042.72 | 276,466,648.37 |
| 归属于母公司股东的净利润 | 164,234,071.15 | 135,434,159.83 | 71,080,090.21 | 247,697,195.98 |
| 少数股东损益 | 26,274,967.19 | 19,472,000.05 | 10,902,952.51 | 28,769,452.39 |
| (一)基本每股收益 | 0.2 | 0.17 | 0.09 | 0.3 |
| (二)稀释每股收益 | 0.2 | 0.17 | 0.09 | 0.3 |
| 八、其他综合收益 | - | - | - | -3,222,911.66 |
| 归属于母公司股东的其他综合收益 | - | - | - | -3,222,911.66 |
| 九、综合收益总额 | 190,509,038.34 | 154,906,159.88 | 81,983,042.72 | 273,243,736.71 |
| 归属于母公司股东的综合收益总额 | 164,234,071.15 | 135,434,159.83 | 71,080,090.21 | 244,474,284.32 |
| 归属于少数股东的综合收益总额 | 26,274,967.19 | 19,472,000.05 | 10,902,952.51 | 28,769,452.39 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-30 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |